Development of fibroblast activation protein-targeted radiotracers with improved tumor retention
Cancer-associated fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas. The overexpression of the serine protease fibroblast activation protein (FAP) allows a selective targeting of a variety of tumors by inhibitor-based radiophar...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 8, 2019
|
| In: |
Journal of nuclear medicine
Year: 2019, Jahrgang: 60, Heft: 10, Pages: 1421-1429 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.118.224469 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.2967/jnumed.118.224469 Verlag: http://jnm.snmjournals.org/content/60/10/1421 
|
| Verfasserangaben: | Anastasia Loktev, Thomas Lindner, Eva-Maria Burger, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Frederik Marmé, Dirk Jäger, Walter Mier, and Uwe Haberkorn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1680065203 | ||
| 003 | DE-627 | ||
| 005 | 20230426084707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191028s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.118.224469 |2 doi | |
| 035 | |a (DE-627)1680065203 | ||
| 035 | |a (DE-599)KXP1680065203 | ||
| 035 | |a (OCoLC)1341249384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Loktev, Anastasia |e VerfasserIn |0 (DE-588)1160315728 |0 (DE-627)1023462869 |0 (DE-576)505840170 |4 aut | |
| 245 | 1 | 0 | |a Development of fibroblast activation protein-targeted radiotracers with improved tumor retention |c Anastasia Loktev, Thomas Lindner, Eva-Maria Burger, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Frederik Marmé, Dirk Jäger, Walter Mier, and Uwe Haberkorn |
| 264 | 1 | |c March 8, 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.10.2019 | ||
| 520 | |a Cancer-associated fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas. The overexpression of the serine protease fibroblast activation protein (FAP) allows a selective targeting of a variety of tumors by inhibitor-based radiopharmaceuticals (FAPIs). Of these compounds, FAPI-04 has been recently introduced as a theranostic radiotracer and demonstrated high uptake into different FAP-positive tumors in cancer patients. To enable the delivery of higher doses, thereby improving the outcome of a therapeutic application, several FAPI variants were designed to further increase tumor uptake and retention of these tracers. Methods: Novel quinoline-based radiotracers were synthesized by organic chemistry and evaluated in radioligand binding assays using FAP-expressing HT-1080 cells. Depending on their in vitro performance, small-animal PET imaging and biodistribution studies were performed on HT-1080-FAP tumor-bearing mice. The most promising compounds were used for clinical PET imaging in 8 cancer patients. Results: Compared with FAPI-04, 11 of 15 FAPI derivatives showed improved FAP binding in vitro. Of these, 7 compounds demonstrated increased tumor uptake in tumor-bearing mice. Moreover, tumor-to-normal-organ ratios were improved for most of the compounds, resulting in images with higher contrast. Notably two of the radiotracers, FAPI-21 and -46, displayed substantially improved ratios of tumor to blood, liver, muscle, and intestinal uptake. A first diagnostic application in cancer patients revealed high intratumoral uptake of both radiotracers already 10 min after administration but a higher uptake in oral mucosa, salivary glands, and thyroid for FAPI-21. Conclusion: Chemical modification of the FAPI framework enabled enhanced FAP binding and improved pharmacokinetics in most of the derivatives, resulting in high-contrast images. Moreover, higher doses of radioactivity can be delivered while minimizing damage to healthy tissue, which may improve therapeutic outcome. | ||
| 650 | 4 | |a FAP inhibitor | |
| 650 | 4 | |a fibroblast activation protein | |
| 650 | 4 | |a PET/CT | |
| 650 | 4 | |a theranostics | |
| 650 | 4 | |a tracer development | |
| 700 | 1 | |a Lindner, Thomas |e VerfasserIn |0 (DE-588)107520318X |0 (DE-627)833005804 |0 (DE-576)443314772 |4 aut | |
| 700 | 1 | |a Altmann, Annette |e VerfasserIn |0 (DE-588)1032267984 |0 (DE-627)738189111 |0 (DE-576)379930099 |4 aut | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 700 | 1 | |a Debus, Jürgen |d 1964- |e VerfasserIn |0 (DE-588)1022671421 |0 (DE-627)717025780 |0 (DE-576)365774944 |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Mier, Walter |d 1966- |e VerfasserIn |0 (DE-588)12029026X |0 (DE-627)69653567X |0 (DE-576)292141599 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 60(2019), 10, Seite 1421-1429 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a Development of fibroblast activation protein-targeted radiotracers with improved tumor retention |
| 773 | 1 | 8 | |g volume:60 |g year:2019 |g number:10 |g pages:1421-1429 |g extent:9 |a Development of fibroblast activation protein-targeted radiotracers with improved tumor retention |
| 856 | 4 | 0 | |u https://doi.org/10.2967/jnumed.118.224469 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://jnm.snmjournals.org/content/60/10/1421 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191028 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 11 |y j | ||
| 998 | |g 12029026X |a Mier, Walter |m 12029026X:Mier, Walter |d 910000 |d 911400 |e 910000PM12029026X |e 911400PM12029026X |k 0/910000/ |k 1/910000/911400/ |p 10 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 9 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |d 50000 |e 910000PM132561972 |e 910400PM132561972 |e 50000PM132561972 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 8 | ||
| 998 | |g 1022671421 |a Debus, Jürgen |m 1022671421:Debus, Jürgen |d 910000 |d 911400 |e 910000PD1022671421 |e 911400PD1022671421 |k 0/910000/ |k 1/910000/911400/ |p 7 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 6 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |e 910000PG129031240 |e 911400PG129031240 |k 0/910000/ |k 1/910000/911400/ |p 5 | ||
| 998 | |g 1032267984 |a Altmann, Annette |m 1032267984:Altmann, Annette |d 910000 |d 911400 |e 910000PA1032267984 |e 911400PA1032267984 |k 0/910000/ |k 1/910000/911400/ |p 4 | ||
| 998 | |g 107520318X |a Lindner, Thomas |m 107520318X:Lindner, Thomas |d 50000 |e 50000PL107520318X |k 0/50000/ |p 2 | ||
| 998 | |g 1160315728 |a Loktev, Anastasia |m 1160315728:Loktev, Anastasia |p 1 |x j | ||
| 999 | |a KXP-PPN1680065203 |e 3529271276 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Anastasia","role":"aut","family":"Loktev","display":"Loktev, Anastasia"},{"given":"Thomas","role":"aut","family":"Lindner","display":"Lindner, Thomas"},{"role":"aut","given":"Annette","family":"Altmann","display":"Altmann, Annette"},{"family":"Giesel","display":"Giesel, Frederik L.","role":"aut","given":"Frederik L."},{"display":"Kratochwil, Clemens","family":"Kratochwil","given":"Clemens","role":"aut"},{"display":"Debus, Jürgen","family":"Debus","given":"Jürgen","role":"aut"},{"role":"aut","given":"Frederik","family":"Marmé","display":"Marmé, Frederik"},{"family":"Jäger","display":"Jäger, Dirk","given":"Dirk","role":"aut"},{"given":"Walter","role":"aut","family":"Mier","display":"Mier, Walter"},{"family":"Haberkorn","display":"Haberkorn, Uwe","given":"Uwe","role":"aut"}],"language":["eng"],"origin":[{"dateIssuedDisp":"March 8, 2019","dateIssuedKey":"2019"}],"note":["Gesehen am 28.10.2019"],"title":[{"title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","title_sort":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Anastasia Loktev, Thomas Lindner, Eva-Maria Burger, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Jürgen Debus, Frederik Marmé, Dirk Jäger, Walter Mier, and Uwe Haberkorn"]},"physDesc":[{"extent":"9 S."}],"recId":"1680065203","relHost":[{"part":{"extent":"9","volume":"60","pages":"1421-1429","year":"2019","issue":"10","text":"60(2019), 10, Seite 1421-1429"},"titleAlt":[{"title":"JNM"}],"language":["eng"],"corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"id":{"issn":["2159-662X","1535-5667"],"zdb":["2040222-3"],"eki":["325793603"]},"recId":"325793603","name":{"displayForm":["Society of Nuclear Medicine"]},"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retentionJournal of nuclear medicine","origin":[{"dateIssuedDisp":"1964-","publisher":"Soc.","dateIssuedKey":"1964","publisherPlace":"New York, NY"}],"pubHistory":["Nachgewiesen 5.1964 -"],"note":["Gesehen am 13.12.2021"],"title":[{"title":"Journal of nuclear medicine","subtitle":"JNM","title_sort":"Journal of nuclear medicine"}]}],"id":{"eki":["1680065203"],"doi":["10.2967/jnumed.118.224469"]}} | ||
| SRT | |a LOKTEVANASDEVELOPMEN8201 | ||